AUA 2025: State-of-the-Art Lecture: Focal Therapy in Prostate Cancer: Prime Time or Not Time?
AUA 2025 Focal Therapy in Prostate Cancer, ProtecT study, Phase II focal therapy trial,
Related Articles
AUA 2025: An Artificial Intelligence-powered Predictive Biomarker for Response to Intravesical BCG versus Gemcitabine-Docetaxel for High-Grade Non-Muscle Invasive Bladder Cancer
AUA 2025 artificial intelligence-powered predictive biomarker, intravesical BCG versus gemcitabine + docetaxel in high-grade, non-muscle invasive bladder cancer (NMIBC) patients, EA-8212 (BRIDGE), computational histology artificial…
AUA 2025: Preliminary Efficacy and Safety of Disitamab Vedotin Combined with BCG in the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer with HER2 Expression: A Prospective, Open Label, Single-Center Study
AUA 2025 disitamab vedotin combined with BCG for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC), HER2 expression.
AUA 2025: Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer with UGN-102: Ongoing Results from a Single-Arm, Open-Label, Phase 3 Trial (ENVISION)
AUA 2025 results of ENVISION, UGN-102, non-muscle invasive bladder cancer (NMIBC), ENVISION trial, urinary retention, urethral stenosis.
AUA 2025: Cost-Effectiveness Analysis of 89Zr-Girentuximab PET—CT (TLX250) to Guide Management of Small Renal Masses
AUA 2025 cost-effectiveness analysis of 89Zr-girentuximab PET-CT (TLX250) to guide management of small renal masses,
AUA 2025: Are Veterans with Prostate Cancer Scientifically Underserved? Describing Access to Prostate Cancer Clinical Trials in the VA
AUA 2025 prostate cancer clinical trials in the VA, veterans with prostate cancer, VA healthcare system.
AUA 2025: TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin–unresponsive Papillary Disease–only High-Risk Non–muscle-Invasive Bladder Cancer: First Results from Cohort 4 of SunRISe-1
AUA 2025, non–muscle-invasive bladder cancer (NMIBC), TAR-200 monotherapy, SunRISe-1 trial, BCG-unresponsive disease.
AUA 2025: BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ.
AUA 2025 BOND-003 Cohort C, Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ.
AUA 2025: Crossfire: Controversies in Urology: Double Intravesical Chemotherapy is Preferred Over New FDA Approved Agents for BCG Unresponsive NMIBC: The Price of Success
AUA 2025, non muscle invasive bladder cancer (NMIBC), BCG Unresponsive NMIBC, nadofaragene, KEYNOTE-057 study, gemcitabine-docetaxel.
Sign up
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
AUA 2025: Dissecting Genomic Features of BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Identifies Drivers of Sensitivity to Intravesical Gemcitabine/Docetaxel
AUA 2025 non-invasive bladder cancer, genomic drivers of sensitivity to intravesical gemcitabine + docetaxel, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).